Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes

2015 ◽  
Vol 21 (2) ◽  
pp. 262-269 ◽  
Author(s):  
Chiyomi Egawa ◽  
Kouichi Hirokaga ◽  
Shintaro Takao ◽  
Kazuhiko Yamagami ◽  
Masaru Miyashita ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cohort Study ◽  
Cancer Patients ◽  
Patient Reported Outcomes ◽  
Breast Cancer Patients ◽  
Multicenter Cohort Study ◽  
Multicenter Cohort ◽  
Patient Reported ◽  
Joint Symptoms

Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study

Breast Cancer ◽  
2011 ◽  
Vol 19 (3) ◽  
pp. 253-258 ◽  
Author(s):  
Masataka Sawaki ◽  
Hirofumi Mukai ◽  
Nahomi Tokudome ◽  
Takahiro Nakayama ◽  
Naruto Taira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Multicenter Cohort Study ◽  
Adjuvant Trastuzumab ◽  
Multicenter Cohort ◽  
Her 2

scholarly journals Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study

2021 ◽  
Vol 11 ◽  
Author(s):  
Ling Xu ◽  
Yinhua Liu ◽  
Zhimin Fan ◽  
Zefei Jiang ◽  
Yunjiang Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Maximum Likelihood Estimates ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Multicenter Cohort Study ◽  
Trastuzumab Therapy ◽  
Multicenter Cohort

This study was to assess the prognosis stratification of the clinical-pathologic staging system incorporating estrogen receptor (ER)-negative disease, the nuclear grade 3 tumor pathology (CPS + EG), Neo-Bioscore, and a modified Neo-Bioscore system in breast cancer patients after preoperative systemic therapy (PST). A retrospective multicenter cohort study was conducted from 12 participating hospitals’ databases from 2006 to 2015. Five-year disease free survival (DFS), disease specific survival (DSS), and overall survival (OS) were calculated using Kaplan–Meier Method. Area under the curve (AUC) of the three staging systems was compared. Wald test and maximum likelihood estimates in Cox proportional hazards model were used for multivariate analysis. A total of 1,077 patients were enrolled. The CPS + EG, Neo-Bioscore, and modified Neo-Bioscore could all stratify the DFS, DSS, and OS (all P < 0.001). While in the same stratum of Neo-Bioscore scores 2 and 3, the HER2-positive patients without trastuzumab therapy had much poorer DSS (P = 0.013 and P values < 0.01, respectively) as compared to HER2-positive patients with trastuzumab therapy and HER2-negative patients. Only the modified Neo-Bioscore had a significantly higher stratification of 5-year DSS than PS (AUC 0.79 vs. 0.65, P = 0.03). So, the modified Neo-Bioscore could circumvent the limitation of CPS + EG or Neo-Bioscore.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT03437837.

Sign in / Sign up

Export Citation Format

Share Document